Follow-Up Health Update for Breast Implant Patients
Last week, I informed you of breaking news about breast implants and ALCL (Anaplastic Large Cell Lymphoma). The FDA recently issued an update, which was reported this week in Cosmetic Surgery Times and summarized below:
In a press briefing, William Maisel, M.D. of the FDA’s Center for Devices and Radiological Health said, “We need more data and are asking that healthcare professionals tell us about any confirmed cases they identify. We are working with the American Society of Plastic Surgeons and other experts in the field to establish a breast-implant patient registry, which should help us better understand the development of ALCL in women with breast implants.” The agency also will work with implant manufacturers to update product labeling information.
Other review results discussed during the press briefing:
• Most of the ALCL cases were diagnosed after silicone implants returned to the market in 2006.
• The diagnoses tended to occur a median of eight years after implantation
• Most lesions arose in the fibrous capsule that formed around the implant.
• A majority of cases involved implants for breast augmentation as opposed to reconstruction following breast cancer surgery.
If you have any questions, the FDA has made a consumer information brochure available on their website at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm240985.htm or go to the combined specialty ASPS/ASAPS websited http://www.breastimplantsafety.org/ or ask your plastic surgeon, or feel free to contact me.